The goal of this observational, practice-based feasibility study is to observe the efficacy and safety of intramuscular administration of Stempeucel® in Malaysian patients with critical limb ischemia (CLI) due to peripheral arterial disease. The main questions it aims to answer are: * Can intramuscular administration of Stempeucel® reduce symptoms of CLI due to peripheral arterial disease while improving the healing rate and functional outcomes? * Does intramuscular administration of Stempeucel® causes any serious adverse events in CLI due to peripheral arterial disease patients? Study patients will be assessed by the PI before administering the Stempeucel® for any other organ with inflammation. The study patients will also be followed up to the duration of 1 year after study treatment administration for safety and efficacy assessment.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in ischemic rest pain
Timeframe: Screening (Day -14 to -1), Day 30, 90, 180 and 360
Change in size of the ulcer
Timeframe: Screening (Day -14 to -1), Day 30, 90, 180 and 360
Change in ankle brachial pressure index (ABPI)
Timeframe: Screening (Day -14 to -1), Day 30, 90, 180 and 360
Change in total walking distance
Timeframe: Screening (Day -14 to -1), Day 30, 90, 180 and 360
Change in major amputation-free survival
Timeframe: Screening (Day -14 to -1), Day 30, 90, 180 and 360
Change in angiogenesis
Timeframe: Screening (Day -14 to -1), Day 180